THE PH-DEPENDENT REDUCTION OF ADRIAMYCIN CATALYZED BY NADH-CYTOCHROME B(5) REDUCTASE

被引:9
作者
HODNICK, WF
SARTORELLI, AC
机构
[1] YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA
[2] YALE UNIV, SCH MED, CTR COMPREHENS CANC, NEW HAVEN, CT 06520 USA
关键词
ADRIAMYCIN; NADH-CYTOCHROME B(5) REDUCTASE; PH; REACTIVE OXYGEN; CYSTEINE;
D O I
10.1016/0304-3835(94)90369-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adriamycin is a redox active antineoplastic antibiotic that upon reduction can, in the presence of oxygen, redox cycle to form reactive oxygen species, while in anaerobiosis can generate a reactive quinone methide. NADH:cytochrome b(5) reductase catalysed the reduction of adriamycin at pH 6.6 with an apparent K-m of 1.8 mu M; at pH 7.6, no measurable reduction of adriamycin occurred. Aerobically, in the presence of enzyme and NADH, adriamycin stimulated oxygen consumption and concomitant accumulation of hydrogen peroxide. At pH 7.6, no discernible oxygen consumption nor detectable hydrogen peroxide generation was observed. The findings demonstrate that NADH:cytochrome b(5) reductase is capable of reducing adriamycin, in a pH-dependent manner, to species that can redox cycle in the presence of oxygen to form reactive oxygen molecules and thus may contribute to the generation of oxidative stress, a phenomenon suggested to be involved in both the toxicity and the antineoplastic activity of adriamycin.
引用
收藏
页码:149 / 154
页数:6
相关论文
共 35 条
[1]  
AEBI H, 1984, METHOD ENZYMOL, V105, P121
[2]   NADPH CYTOCHROME-P-450 REDUCTASE ACTIVATION OF QUINONE ANTI-CANCER AGENTS TO FREE-RADICALS [J].
BACHUR, NR ;
GORDON, SL ;
GEE, MV ;
KON, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (02) :954-957
[3]  
BACHUR NR, 1978, CANCER RES, V38, P1745
[4]  
BARABAS K, 1992, J BIOL CHEM, V267, P9437
[5]  
BORGESE N, 1982, J BIOL CHEM, V257, P13854
[6]  
BURKE TG, 1987, CANCER BIOCHEM BIOPH, V9, P245
[7]   ADRIAMYCIN - REVIEW [J].
CARTER, SK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 55 (06) :1265-1274
[8]   THE CONSEQUENCES OF DOXORUBICIN QUINONE REDUCTION INVIVO IN TUMOR-TISSUE [J].
CUMMINGS, J ;
WILLMOTT, N ;
HOEY, BM ;
MARLEY, ES ;
SMYTH, JF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (11) :2165-2174
[9]  
DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068
[10]  
GIANNI L, 1983, REV BIOCHEM TOXICOL, P1